Have a personal or library account? Click to login
Overview of Host Defense Peptides with Promising Anti-Breast Cancer Activity Cover

Overview of Host Defense Peptides with Promising Anti-Breast Cancer Activity

Open Access
|Oct 2022

Abstract

Breast cancer is the leading cause of death among women worldwide. The main limitations of conventional anti-cancer therapy, including breast cancer treatment, are side effects and the development of resistance to chemotherapeutics. Host defense peptides (HDPs) are bioactive compounds of innate immunity isolated from almost all living organisms, which exhibit wide range of biological activities. This review focuses on the anti-cancer effects of HDPs and their therapeutic potential against breast cancer. Numerous HDPs from different sources, including mammalian and amphibian origin, and their chemically modified analogues, exert the spectrum of anti-cancer activities. These effects include direct disruption of cancer cell membrane, induction of apoptosis, inhibition of angiogenesis and cancer cell proliferation, but also the modulation of anti-cancer immune response. Selected examples of HDPs of different origin and their anti-breast cancer capacities have been reviewed. Conclusively, due to their anti-cancer effects accompanied by substantial selectivity for cancer cells and low toxicity for normal cells, HDPs have been widely recognized as possible therapeutic agents.

DOI: https://doi.org/10.2478/sjecr-2021-0052 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Language: English
Submitted on: Jun 30, 2021
Accepted on: Jul 27, 2021
Published on: Oct 14, 2022
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Sanja Zornic, Bojana Lukovic, Andra Jevtovic, Jelena D. Dimitrijevic, Bojana Simovic Markovic, Jelena Pantic, Gordana D. Radosavljevic, Nebojsa Arsenijevic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT